NCT00077376View on ClinicalTrials.gov

Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2011

Conditions
HER2-positive Breast CancerMale Breast CancerRecurrent Breast CancerStage IV Breast Cancer
Interventions
BIOLOGICAL

trastuzumab

Given IV

DRUG

ixabepilone

Given IV

DRUG

carboplatin

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

02215

Eastern Cooperative Oncology Group, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00077376 - Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter